This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Digging into the potential of AYVAKIT (avapritinib) as part of treatment in patients with non advanced systemic mastocytosis
Ticker(s): BPMCWho's the expert?
Institution: Scripps Clinic
- Allergist/Immunologist & Director, Aspirin Exacerbated Respiratory Disease Clinic,Division of Allergy, Asthma and Immunology at the Scripps Clinic.
- Currently manages 35 patients with systemic mastocytosis.
- Focus is on Aspirin exacerbated respiratory disease (AERD), mastocytosis, and mast cell activation syndromes; conducts research on aspirin exacerbated respiratory disease, a topic on which he has authored multiple publications and ongoing research protocols.
Interview GoalThis conversation will focus on discussing the recent positive top-line results announcement by Blueprint Medicines for Ayvakit (avapritinib) achieving primary and all key secondary endpoints from the PIONEER trial of in treating patients with non-advanced systemic mastocytosis
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
